Consensus Sutro Biopharma, Inc.

Stocks

STRO

US8693672011

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 17:45:33 01/10/2026 +04			5-day change	1st Jan Change
16.10 ^USD	-0.06%		+2.42%	+39.24%

09-29	Sutro Biopharma, Inc. Announces Appointment of Lucas Donigian as Senior Vice President, Business Development, Effective September 28, 2026	CI
09-21	Sutro Biopharma, Inc.(NasdaqGM:STRO) added to S&P Global BMI Index	CI

Evolution of the Average Target: Sutro Biopharma, Inc.

Evolution of the Target Price: Sutro Biopharma, Inc.

Changes in Analyst Recommendations: Sutro Biopharma, Inc.

d4143c70348237a23553c172.V-nq0sxPBwEPKFQdWBVIVmB_kjBYp6zzyXvsW46GVzA.D4Xf4ZYCZWp5biFJOkR9PiQF_XI76sTHhT64HfTcM3o-g7OxniB9SDZQYA~ccb3854bc0454279dea63145958a9b13

Analysts' recommendations: Sutro Biopharma, Inc.

05-28	Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target	MT
05-15	Sutro Biopharma Shares Rise After Q1 Loss Narrows	MT
05-15	Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22	MT
04-30	Mizuho Initiates Sutro Biopharma at Outperform With $50 Price Target	MT
04-07	Leerink Partners Initiates Sutro Biopharma at Outperform With $38 Price Target	MT
03-25	Deutsche Bank Adjusts Sutro Biopharma Price Target to $55 From $51, Maintains Buy Rating	MT
03-24	Wells Fargo Upgrades Sutro Biopharma to Overweight From Equal Weight, Adjusts PT to $27 From $8	MT
03-24	HC Wainwright Upgrades Sutro Biopharma to Buy From Neutral, Adjusts PT to $28 From $10	MT
03-24	Wedbush Raises Price Target on Sutro Biopharma to $22 From $10, Keeps Neutral Rating	MT
12-17	Deutsche Bank Boosts Price Target on Sutro Biopharma to $51 From $5, Keeps Buy Rating	MT
16/06/25	Piper Sandler Upgrades Sutro Biopharma to Overweight From Neutral, $2 Price Target	MT
17/03/25	HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2	MT
17/03/25	Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform	MT
17/03/25	Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating	MT
14/03/25	Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8	MT
14/03/25	Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8	MT
14/03/25	Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating	MT
16/08/24	Truist Securities Adjusts Price Target on Sutro Biopharma to $15 From $18, Maintains Buy Rating	MT
08/05/24	BofA Securities Starts Sutro Biopharma With Buy Rating	MT
03/04/24	Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	MT
03/04/24	Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	MT
26/03/24	Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	MT
15/11/23	Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating	MT
06/10/23	Oppenheimer Initiates Coverage on Sutro Biopharma With Outperform Rating, $10 Price Target	MT
11/08/23	Wedbush Cuts Sutro Biopharma's PT to $12 From $20, Pushes Back Estimated Launch of STRO-002, Adjusts Capital Raise Assumptions; Keeps Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SUTRO BIOPHARMA, INC.					+193.18%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+21.92%
	LONZA GROUP AG					+19.64%
	IQVIA HOLDINGS INC.					+7.4%
	REVOLUTION MEDICINES, INC.					+25.43%
	BEONE MEDICINES AG					+18.27%
	CELLTRION, INC.					+50.7%
	WUXI BIOLOGICS (CAYMAN) INC.					+3.91%
	INSMED INCORPORATED					+73.24%
	Average					+42.55%
	Weighted average by Cap.					+22.31%